MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
Mutual FundPosition in GYRE — Gyre Therapeutics, Inc.
CIK 1705339
CAUSEWAY BAY, K3
Position in GYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$55,659
+$16,509 QoQ
Shares Held
8,446
+50.4% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#32
of 60 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. holds $436,017,852 across 285 Biotechnology names. GYRE ranks #269 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
150,692 | $74,853,236 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
59,595 | $37,159,864 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
63,265 | $19,044,662 | |
| 4 | RPRX |
Royalty Pharma plc
|
259,390 | $14,543,997 | |
| 5 | INCY |
Incyte Corp
|
83,084 | $9,418,401 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
27,185 | $9,101,265 | |
| 7 | MRNA |
Moderna, Inc.
|
106,564 | $7,462,676 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
122,658 | $6,689,766 |
All Filings in GYRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $55,659 | 8,446 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $39,150 | 5,617 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $38,695 | 5,481 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $31,354 | 4,203 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $54,485 | 7,413 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $32,184 | 4,169 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $48,557 | 4,013 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $48,416 | 3,861 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||